albumin - publications

Predict more albumin - ligand interactions now!


1. Cancer Biol Ther. 2012 Feb 15;13(4):206-15.

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic
cancer therapy.

Ji S, Xu J, Zhang B, Yao W, Xu W, Wu W, Xu Y, Wang H, Ni Q, Hou H, Yu X.

Department of Pancreas and Hepatobiliary Surgery; Fudan University Shanghai
Cancer Center; Department of Oncology; Shanghai Medical College; Fudan
University; Shanghai, China; These authors contributed equally to this article.

Integrin αvβ3 receptor is expressed on several types of cancer cells, including
pancreatic cancer cells, and plays an important role in tumor growth and
metastasis. The ability to target the integrin αvβ3 receptor on cancer cells
increases the efficacy of targeted therapy and reduces the side effects. The aim
of this study is to develop a novel arginine-glycine-aspartic acid (RGD) peptide
-conjugated albumin nanoparticle to enhance the intracellular uptake of
anticancer drug into the pancreatic cancer cells through receptor-mediated
endocytosis. In the cellular uptake studies, the fluorescent signal of
RGD-conjugated BSANPs in BxPC3 cells was higher than that of BSANPs without RGD
conjugation as determined by fluorescence spectrophotometer. We also found that
BSANPs bound to BxPC3 cells in a time- and concentration-dependent manner. The
uptake of RGD-conjugated BSANPs by pancreatic cancer cells was inhibited by an
excess amount of free RGD peptide, indicating that the binding and/or uptake were
mediated by the αvβ3 receptor. Furthermore, the nanoparticles were found to be
located close to the nuclei by using laser scanning confocal microscopy. Besides,
no significant in vitro cytotoxicity was observed as measured with MTT assay.
Both in vitro and in vivo antitumor efficacy was improved by targeting
gemcitabine-loaded nanoparticles to BxPC-3 cells using RGD peptides. Therefore,
the RGD-conjugated BSANPs hold great potential as an effective drug delivery
system to deliver therapeutic agents to pancreatic cancer.

PMID: 22354009 [PubMed - in process]